India, May 15 -- This week's biotech highlights Lilly's strong Phase 3b maintenance results for Zepbound and Foundaya, Rigel's global license for the first FDA-approved PROTAC therapy Veppanu, and Bristol Myers Squibb's $15.2 billion collaboration with Hengrui Pharma. The regulatory front saw ATyr refining its Phase 3 path for Efzofitimod, Apyx gaining expanded AYON clearance, and argenx broadening VYVGART's label. On the clinical side, Alpha Tau, SELLAS, and Lilly reported positive updates across oncology, hematology, and obesity.
Let's unpack the specifics.
FDA Approvals and Rejections
ATyr Pharma Refines Phase 3 Path for Efzofitimod in Sarcoidosis
aTyr Pharma, Inc. (ATYR) outlined updated regulatory guidance and clinical plans for Ef...